Salvatore Brugaletta

Salvatore Brugaletta

Interventional cardiologist / Cardiologist
Clinic Cardiovascular Institute - Barcelona, Spain

Latest contributions

Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation

04 Apr 2018

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

New-onset atrial fibrillation after PCI or CABG for left main disease : The EXCEL Trial

15 Feb 2018

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicenter FITT-STEMI trial

15 Feb 2018

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta
Dejan Milasinovic

Reviewer

Dejan Milasinovic

Long-term outcomes with TAVR in women compared with men - Evidence from a meta-analysis

18 Jan 2018

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Transcatheter aortic valve replacement in pure native aortic valve regurgitation

15 Jan 2018

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Results of the 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II Late Breaking Trials: TCT 2017

01 Nov 2017

After the presentation of the data coming from 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II, the interventional cardiology community is even more divided into those in favor or not of Bioresorbable Scaffold (BRS) technology. Many interesting points of discussion arise from these data.

Salvatore Brugaletta

Author

Salvatore Brugaletta

Results of the 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II Late Breaking Trials: TCT 2017

01 Nov 2017

After the presentation of the data coming from 30-day ABSORB IV, 3-year ABSORB III and 4-year ABSORB II, the interventional cardiology community is even more divided into those in favor or not of Bioresorbable Scaffold (BRS) technology. Many interesting points of discussion arise from these data.

Salvatore Brugaletta

Author

Salvatore Brugaletta

PCR @ TCT 2017

We will be covering a selection of major Late-breaking Clinical Trials in Interventional Cardiology to be released at the 2017 Transcatheter Cardiovascular Therapeutics Scientific Sessions. Get the European Perspective!

Printed MDCT 3D models for prediction of left atrial appendage (LAA) occluder device size: a feasibility study

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial

06 Sep 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

2017 ESC Guidelines on Acute Myocardial Infarction in patients presenting with ST-segment elevation (STEMI)

30 Aug 2017

Of the four guidelines released at the ESC Congress 2017, the STEMI guidelines may probably represent one of the most interesting for our community. Many of the changes in recommendations were already expected by many of us, whereas others are important to see and to digest.

Salvatore Brugaletta

Author

Salvatore Brugaletta

PCR @ ESC Congress 2017

We will be providing live updates on a selection of major Late Breaking Scientific Sessions of interest to Interventional Cardiologists during ESC Congress 2017.

COOL AMI EU pilot trial: a multicentre, prospective, randomised controlled trial to assess cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction

10 Aug 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

At least seven days delayed stenting using minimalist immediate mechanical intervention (MIMI) in ST-segment elevation myocardial infarction: the SUPER-MIMI study

02 Aug 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Omission of predilation in balloon-expandable transcatheter aortic valve implantation: retrospective analysis in a large-volume centre

20 Jun 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Impact of implantation technique on BRS outcomes

18 May 2017 – From EuroPCR 2017

Bioresorbable scaffolds: an evolving technology

17 May 2017 – From EuroPCR 2017

Coronary perforation during PCI

16 May 2017 – From EuroPCR 2017

Coronary interventions - advanced IV

16 May 2017 – From EuroPCR 2017

Complications

15 May 2017 – From EuroPCR 2017

Clinical research

15 May 2017 – From EuroPCR 2017

Coronary interventions – advanced I

15 May 2017 – From EuroPCR 2017

Coronary interventions – the basics II

15 May 2017 – From EuroPCR 2017

Coronary interventions – the basics I

15 May 2017 – From EuroPCR 2017

Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve

29 Mar 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Pulsatile iVAC 2L circulatory support in high-risk percutaneous coronary intervention

08 Mar 2017

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Percutaneous coronary intervention using a combination of robotics and telecommunications by an operator in a separate physical location from the patient

27 Jan 2017

S. Brugaletta reviews an article from EuroIntervention on an early exploration into the feasibility of telestenting (the REMOTE-PCI study)

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score)

16 Dec 2016

S. Brugaletta reviews an article from EuroIntervention on a tool using age, thrombotic burden and index microcirculatory resistance to predict the outcome of reperfusion.

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta

Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial

14 Nov 2016

Salvatore Brugaletta

Reviewer

Salvatore Brugaletta